Related Experiment Video
Updated: Jan 16, 2026
An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth
Published on: September 22, 2021
Cytotoxicity of Esculetin Compared with Vinblastine and Paclitaxel in PC-3 Prostate Cancer Cells
Ana I García-Pérez1, Virginia Rubio1, Angel Herráez1
1Unidad de Bioquímica y Biología Molecular, Departamento de Biología de Sistemas, Universidad de Alcalá, 28805 Alcalá de Henares, Spain.
Background/Objectives:
Metastatic prostate cancer is among the therapy-resistant human neoplasms. PC-3 is a commonly used experimental cell line that does not express androgen receptors. We compared the cytotoxicity of esculetin with that of vinblastine and paclitaxel on prostatic tumour PC-3 cells.
Methods:
Cells were treated with either esculetin (100 or 250 μM), vinblastine (50 μM) or paclitaxel (100 or 200 μM) for 19 to 72 h. Cells were assessed for metabolic viability, membrane integrity, DNA fragmentation and cell cycle analysis. Apoptosis was checked with annexin and propidium iodide.
Results:
Esculetin decreased the metabolic activity of PC-3 cells in a time- and concentration-dependent way. The metabolic activity of vinblastine- and paclitaxel-treated cells did not show time-dependence. Cells treated with 250 µM esculetin for 48 or 72 h showed apoptosis levels similar to those produced by 50 µM vinblastine at these incubation times or by 200 µM paclitaxel at 19 h. Vinblastine and paclitaxel produced cell cycle arrest in the G2/M phase after incubation for 19 h. In contrast, esculetin did not significantly affect the cell cycle.
Conclusions:
A differential action of esculetin on PC-3 prostate cells may be inferred. This may be relevant for novel therapies against resistant prostate cancer.
Insights
Esculetin shows potential as a novel therapy for resistant prostate cancer by inducing apoptosis in PC-3 cells. Unlike vinblastine and paclitaxel, esculetin does not cause cell cycle arrest, suggesting a differential mechanism of action.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Metastatic prostate cancer is a therapy-resistant neoplasm.
- PC-3 cells, commonly used in research, lack androgen receptors.
- Investigating novel therapeutic agents for resistant prostate cancer is crucial.
Purpose of the Study:
- To compare the cytotoxicity of esculetin, vinblastine, and paclitaxel on PC-3 prostate cancer cells.
- To evaluate the effects of these agents on cell viability, membrane integrity, DNA fragmentation, and cell cycle progression.
- To assess the induction of apoptosis by esculetin and compare it with standard chemotherapeutics.
Main Methods:
- PC-3 cells were treated with esculetin (100 or 250 μM), vinblastine (50 μM), or paclitaxel (100 or 200 μM) for 19–72 hours.
- Assays included metabolic viability, membrane integrity, DNA fragmentation, and cell cycle analysis.
- Apoptosis was quantified using annexin and propidium iodide staining.
Main Results:
- Esculetin reduced PC-3 cell metabolic activity in a time- and concentration-dependent manner.
- Apoptosis levels induced by esculetin (250 μM for 48/72 h) were comparable to vinblastine (50 μM) and paclitaxel (200 μM).
- Vinblastine and paclitaxel caused G2/M cell cycle arrest, whereas esculetin did not significantly affect the cell cycle.
Conclusions:
- Esculetin exhibits a differential mechanism of action on PC-3 prostate cancer cells compared to vinblastine and paclitaxel.
- The observed apoptosis induction suggests esculetin's potential as a novel therapeutic agent for therapy-resistant prostate cancer.
- Further research into esculetin's unique properties may lead to new treatment strategies for advanced prostate cancer.
